phosphodiesterase-1 inhibitorscolitis
…days (IQR 59-214). The most common immunotherapy treatment were phosphodiesterase-1 inhibitors (49.3%).Cancer treatment common adverse events (CTCAE) grades 1…
10,506articles mentioning drugs
58,393drug mentions
9,496distinct drugs extracted
0%of mentions human-reviewed
All extracted drugs
Showing 541–600 of 9,496, ordered by supporting articles. Choose a drug to see its evidence.
N-Acetyl Cysteine7PPIs7Streptozotocin7fondaparinux7high-dose corticosteroids7hydroxyurea7naltrexone7tyrosine kinase inhibitors7vaccines7SGLT-2i6Glipizide6BLV6Varenicline6Camrelizumab6Cancer Drugs6Benzene6Doxy-PEP6SGLT-2is6Aprepitant6DEX6Dostarlimab6T-DXd6Azacitidine6Esketamine6NAC6Fidaxomicin6ITM6Minocycline6N-acetylcysteine6pMDIs6NBCA6Clofazimine6Filgotinib6Ravulizumab6Atomoxetine6Methylphenidate6amoxicillin-clavulanate6Acetylcysteine6Triamcinolone6anti-PD16Nitrous oxide6Octreotide6injectate6IL-1β6Lenalidomide6OAC6Venetoclax6antihypertensive drugs6n-BCA6Anti-TNF6Golimumab6Placebo6aripiprazole6b/tsDMARDs6Lansoprazole6MDPV6Mitomycin C6Nalbuphine6PCSK9 inhibitors6Sodium-Glucose Co-Transporter 2 Inhibitors6
Articles mentioning drugs
10,506 articles · page 644 of 876IPAADistrict General Hospitalcolorectal cancerulcerative colitisCrohn’s DiseaseCollagenous colitis
…ctomy49 years (43 – 64)Subsequent ileal-pouch anal anastomosis (IPAA)16/78 (20.5%), median interval 13 months (10 – 40)Completion pr…
capsule spongecapsule sponge
…ting risks to access, quality and cost-efficiency. Substituting capsule sponge for a defined proportion of low-risk upper gastrointestinal end…
DTTgastric canceriron deficiency anaemiadiverticular diseasecolorectal cancerangiodysplasiaGastroenterology consultantscolonic polyps
…ere saved in the post-SOP group, equating to 482 OPAs per year. DTT digital triage is well accepted by patients, as evidenced by lo…
Bolus PPINational Institute for Health and Clinical ExcellenceAUGIBNHS Scotlandupper GI bleedingupper GI bleedNICENHS Scotland trusts
…sis of bolus PPI for upper GI bleed management in NHS Scotland. Bolus PPI was demonstrated as non-inferior to UK audit standards across a…
89.9%
Ensure® PlusSjögren’s diseasehypochlorhydriaIBSirritable bowel syndromefunctional dyspepsia
…for 30 minutes then patients ingested 120 ml of nutrient shake (Ensure® Plus, 180 kcal) mixed with 120 ml of water as per the protocol sugge…
OTSCNVUGIBOTSCnon-variceal upper gastrointestinal bleeding
…ed controlled trials (RCTs) have compared over the scope clips (OTSC) with standard endoscopic treatments for first line treatment o…
HM-JACKarccolorectal cancerCRCNHS TaysideIBDSBDinflammatory bowel diseaseUKAS-accredited laboratory
…een 1 Jan 2016 and 31 Dec 2023. Buffered samples were analysed (HM-JACKarc) in a UKAS-accredited laboratory. Results were extracted from t…
78.5%
A23187colorectal cancerinflammatory bowel diseasebile acid diarrhoeaIBD
…e human mast cell line HMC-1.1 (n=4 repeats; ± 50 nM PMA + 1 μM A23187), and differentiated human colonic organoids as a model of the …
CytoLytPancreatic tissue autolysis
…as not used. Interventions included: preservative optimization (CytoLyt to PreservCyt), standardized specimen collection (stylet extrus…
proton pump inhibitorBarrett’s oesophagusintramucosal carcinomaKing’s Lynn HospitalAddenbrooke’s Hospitaldysplasia
…opic reassessment following medical optimisation with high dose proton pump inhibitor. p53 immunohistochemistry showed limited sensitivity for predic…
proton pump inhibitorsGastroesophageal reflux diseaseNHSanti-reflux mucosal interventionshiatal herniaGERD
…py.Results At final follow-up, 53% of patients had discontinued proton pump inhibitors while 64% were not discharged. Only 40% of patients were satisf…